| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 24.059 | 43.634 | 37.195 | 27.728 | 34.486 | 35.516 |
| Total Income - EUR | - | - | - | - | 24.059 | 43.984 | 37.663 | 27.823 | 34.619 | 35.516 |
| Total Expenses - EUR | - | - | - | - | 122 | 82 | 541 | 231 | 532 | 218 |
| Gross Profit/Loss - EUR | - | - | - | - | 23.937 | 43.903 | 37.122 | 27.592 | 34.087 | 35.298 |
| Net Profit/Loss - EUR | - | - | - | - | 23.215 | 42.586 | 36.006 | 26.761 | 28.633 | 29.650 |
| Employees | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Pharmasense Consultancy S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | - | 13.675 | 34.922 | 29.475 | 20.172 | 33.474 | 36.366 |
| Inventories | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 6.741 | 9.572 | 8.743 | 14.646 | 21.877 | 32.530 |
| Cash | - | - | - | - | 6.934 | 25.350 | 20.733 | 5.526 | 11.597 | 3.835 |
| Shareholders Funds | - | - | - | - | 9.737 | 31.537 | 25.203 | 14.034 | 31.366 | 30.004 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 3.938 | 3.385 | 4.273 | 6.138 | 2.107 | 6.814 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7490 - 7490" | |||||||||
| CAEN Financial Year |
7490
|
|||||||||
Comments - Pharmasense Consultancy S.r.l.